Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanidatamab with chemotherapy with or without tislelizumab versus trastuzumab with chemotherapy in HER2-positive advanced gastroesophageal adenocarcinoma
NL-OMON59916Phase 3Active, not recruiting
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in gastroesophageal junction adenocarcinoma comparing Zanidatamab + chemotherapy, Zanidatamab + chemotherapy + tislelizumab and Trastuzumab + chemotherapy (3 arms). Primary endpoints: Progression-free survival and Overall survival. Started May 2022; status: active, not recruiting.
02
Drugs
03
Conditions
gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NL-OMON59916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59916.